

August 8, 2022

The Manager – Listing
BSE Limited,
1st Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai 400001

The Manager – Listing
National Stock Exchange of India Ltd.
Exchange plaza, 5th Floor, Plot No.C/1, G Block
Bandra-Kurla Complex, Bandra (E),
Mumbai 400051

Dear Sir(s),

Sub: Outcome of the Board Meeting held on Monday, August 8, 2022

Ref: Scrip Code - BSE: 506820 / NSE: ASTRAZEN

At the Board meeting of the Company held on Monday, August 8, 2022 the Board of Directors considered and approved the Unaudited Financial Results of the Company for the quarter ended June 30, 2022. The said Unaudited Financial Results together with the Limited Review report of the Statutory Auditors dated August 8, 2022 are enclosed herewith.

The Board meeting concluded at 1.20 p.m.

Please take the same on record.

Thanking you,

For AstraZeneca Pharma India Limited


Pratap Rudra
Company Secretary & Legal Counsel



AstraZeneca Pharma India Limited
Regd. Office : Block M1, 12th Floor, Manyata Embassy Business Park, Rachanahalli, Outer Ring Road, Bangalore 660 045
Statement of unaudited financial results for the quarter ended 30 June 2022

Sl No.	Particulars	Rs in lakhs except for earnings per share data			
		3 months ended 30/06/2022	Previous 3 months ended 31/03/2022	Corresponding 3 months ended in the previous year 30/06/2021	Year ended 31/03/2022
		Unaudited	Refer note 4	Unaudited	Audited
1	Income				
	a) Revenue from operations	23,233.20	23,196.33	17,540.20	80,560.01
	b) Other Income	411.42	368.39	289.98	1,475.76
	Total Income	23,644.62	23,564.72	17,830.18	82,035.77
2	Expenses				
	(a) Cost of materials consumed	1,589.15	2,271.89	1,787.95	8,961.06
	(b) Purchase of stock-in-trade	7,531.44	8,178.58	3,305.88	20,788.07
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(782.80)	307.31	1,572.98	1,447.01
	(d) Employee benefit expense (Refer Note 3)	6,837.12	5,848.31	5,479.34	23,020.62
	(e) Depreciation expense	459.18	440.89	476.08	1,694.89
	(f) Allowance for expected credit loss (net)	99.00	104.74	129.25	399.93
	(g) Selling, marketing and distribution expense	1,073.50	1,813.93	1,028.45	5,071.91
	(h) Other expenses	4,089.31	3,077.43	2,893.26	12,253.94
	(i) Finance costs	18.82	20.71	26.59	94.72
	Total expenses	20,914.72	19,861.87	16,478.78	73,732.15
3	Profit before tax (1-2)	2,729.90	3,703.05	1,350.40	8,303.62
4	Tax expense				
	- Current tax	787.51	921.43	416.85	2,282.94
	- Deferred tax credit	(52.87)	(16.71)	(90.58)	(118.50)
	Total tax expense	714.64	904.72	326.07	2,144.34
5	Profit after tax (3-4)	2,015.26	2,798.33	1,024.33	6,159.28
6	Other comprehensive income/(loss)				
	A. Items that will not be reclassified to profit or loss				
	Re-measurement gains/(losses) on post employment benefit obligations	(9.45)	(117.09)	(12.32)	(231.59)
	Income tax effect on above	2.38	29.47	3.10	58.29
	Total other comprehensive income/ (loss), net of Income tax	(7.07)	(87.62)	(9.22)	(173.30)
	Total comprehensive income for the period (5+6)	2,008.19	2,710.71	1,015.11	5,985.98
7	Paid-up equity share capital (Face value of Rs 2/- per equity share)	500.00	500.00	500.00	500.00
8	Reserves (excluding revaluation reserves as per balance sheet)				50,639.29
9	Earnings per equity share of Rs 2/- each (basic and diluted)	8.06	11.19	4.10	24.84



Yagar

AstraZeneca Pharma India Limited
Regd. Office : Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore 560 045


Statement of unaudited financial results for the quarter ended 30 June 2022

Notes:

- 1 The financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (as amended) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable.
- 2 The Company has identified 'Healthcare Segment' as its only reportable segment. In accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly no segment information has been provided.
- 3 The employee benefit expense for the quarter ended 30 June 2022 includes one-time ex gratia of Rs.998.33 lakhs paid to certain resigned employees.
- 4 The figures for the quarter ended 31 March 2022 are the balancing figures between the audited figures in respect of the full financial year 31 March 2022 and the published unaudited year to date figures up to the third quarter of the respective financial year i.e., 31 December 2021 which were subjected to review by the statutory auditors.
- 5 Previous period's figures have been regrouped/reclassified, where necessary, to conform with the current period's presentation for the purpose of comparability.
- 6 This statement of financial results was reviewed and recommended by the Audit Committee of the Board and subsequently approved by the Board of Directors at their respective meetings held on 08 August 2022. The Statutory auditors of the Company have carried out a limited review of this statement of financial results for the quarter ended 30 June 2022.

Place: Bengaluru
Date: 08 August, 2022

By Order of the Board of Directors
For AstraZeneca Pharma India Limited


Gagandeep Singh Bedi
Managing Director




Price Waterhouse & Co Chartered Accountants LLP

Independent Auditors' Review Report on the Statement of Unaudited Financial Results

To
The Board of Directors
AstraZeneca Pharma India Limited
Block N1, 12th Floor,
Manyata Embassy Business Park
Rachenahalli Outer Ring Road,
Bengaluru – 560 045

1. We have reviewed the unaudited financial results of AstraZeneca Pharma India Limited (the "Company") for the quarter ended June 30, 2022, which are included in the accompanying 'Statement of unaudited financial results for the quarter ended 30 June 2022' and the notes thereon (together referred to as the "Statement"). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015"), which has been initialled by us for identification purposes.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Price Waterhouse & Co Chartered Accountants LLP
Firm Registration Number: 304026E/E-300009



Prasanna Padar Mahabala
Partner

Membership Number: 206477
UDIN: 22206477AOMRRH8404

Place: Bengaluru
Date: August 08, 2022

Price Waterhouse & Co Chartered Accountants LLP, 5th Floor, Tower 'D', The Millenia, 1 & 2 Murphy Road, Ulsoor
Bengaluru - 560 008

T: +91 (80) 4079 5000, F: +91 (80) 4079 5222

Registered office and Head office: Plot No. 56 & 57, Block DN, Sector-V, Salt Lake, Kolkata - 700 091

Price Waterhouse & Co. (a Partnership Firm) converted into Price Waterhouse & Co Chartered Accountants LLP (a Limited Liability Partnership with LLP identity no: LLPIN AAC-4362) with effect from July 7, 2014. Post its conversion to Price Waterhouse & Co Chartered Accountants LLP, its ICAI registration number is 304026E/E300009 (ICAI registration number before conversion was 304026E)